|
|
Article: Roche Licenses Rights To IL-15 Preclinical Program From Cardion.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Hoffmann-La Roche Inc. could find itself paying up to $90 million or more for a preclinical research program with transplant rejection and rheumatoid arthritis applications.
The Nutley, N.J.-based company, an affiliate of the Swiss pharmaceutical giant F. Hoffmann-La Roche Ltd., acquired a product called CRB-15, a human interleukin-15 cytokine receptor blocker, from Cardion AG. In addition to an undisclosed up-front payment and milestone compensation that could total up to $90 million, the Erkrath, Germany-based company is eligible for royalties based on future product sales.
The companies did not disclose more detailed financial ...